HEMATOLOGIC MALIGNANCIES

REFERENCES

• Herman J. G., Baylin S. B. Gene Silencing in Cancer in Association with Promoter Hypermethylation. N. Engl. J. Med. 2003; 349(21)2042–2054
   PubMed Web of Science ®Google Scholar
• Ernst P., Wang J., Korsmeyer S. J. The role of MLL in hematopoiesis and leukemia. Curr. Opin. Hematol. 2002; 9(4)282–287
   PubMed Web of Science ®Google Scholar
• Hess J. L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 2004; 10(10)500–507
   PubMed Web of Science ®Google Scholar
• Li Z. Y., Liu D. P., Liang C. C. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 2005; 19(2)183–190
   PubMed Web of Science ®Google Scholar
• Redner R. L., Wang J., Liu J. M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94(2)417–428
   PubMed Web of Science ®Google Scholar
• Whitman S. P., Liu S., Vukosavljevic T., Rush L. J., Yu L., Liu C., et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005; 106(1)345–352
   PubMed Web of Science ®Google Scholar
• Kurokawa M., Mitani K., Imai Y., Ogawa S., Yazaki Y., Hirai H. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998; 92(11)4003–4012
   PubMed Web of Science ®Google Scholar
• Izutsu K., Kurokawa M., Imai Y., Maki K., Mitani K., Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001; 97(9)2815–2822
   PubMed Web of Science ®Google Scholar
• Sundqvist A., Sollerbrant K., Svensson C. The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett. 1998; 429(2)183–188
   PubMed Web of Science ®Google Scholar
• Kakizuka A., Miller W. H., Jr., Umesono K., Warrell R. P., Jr., Frankel S. R., Murty V. V., et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66(4)663–674
   PubMed Web of Science ®Google Scholar
• Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391(6669)815–818
   PubMed Web of Science ®Google Scholar
• Sirulnik A., Melnick A., Zelent A., Licht J. D. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract. Res. Clin. Haematol. 2003; 16(3)387–408
   PubMed Web of Science ®Google Scholar
• Carapeti M., Aguiar R. C., Goldman J. M., Cross N. C. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 1998; 91(9)3127–3133
   PubMed Web of Science ®Google Scholar
• Ogryzko V. V., Schiltz R. L., Russanova V., Howard B. H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87(5)953–959
   PubMed Web of Science ®Google Scholar
• Bannister A. J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996; 384(6610)641–643
   PubMed Web of Science ®Google Scholar
• Silverman L. R., Demakos E. P., Peterson B. L., Kornblith A. B., Holland J. C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002; 20(10)2429–2440
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Issa J. P., Rosenfeld C. S., Bennett J. M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106(8)1794–1803
   PubMed Web of Science ®Google Scholar
• Silverman L. R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001; 6: 8–14, (Suppl 5)
   PubMed Web of Science ®Google Scholar
• Yang A. S., Doshi K. D., Choi S. W., Mason J. B., Mannari R. K., Gharybian V., et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006; 66(10)5495–503
   PubMed Web of Science ®Google Scholar
• Pinto A., Attadia V., Fusco A., Ferrara F., Spada O. A., Di Fiore P. P. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984; 64(4)922–929
   PubMed Web of Science ®Google Scholar
• Pinto A., Zagonel V., Attadia V., Bullian P. L., Gattei V., Carbone A., et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4: 28–32, (Suppl 3)
   PubMed Web of Science ®Google Scholar
• Attadia V. Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. Leukemia. 1993; 7: 9–16, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Cameron E. E., Bachman K. E., Myohanen S., Herman J. G., Baylin S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999; 21(1)103–107
   PubMed Web of Science ®Google Scholar
• Klisovic M. I., Maghraby E. A., Parthun M. R., Guimond M., Sklenar A. R., Whitman S. P., et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 2003; 17(2)350–358
   PubMed Web of Science ®Google Scholar
• Liu S., Shen T., Huynh L., Klisovic M. I., Rush L. J., Ford J. L., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 2005; 65(4)1277–1284
   PubMed Web of Science ®Google Scholar
• Gore S. D., Baylin S., Sugar E., Carraway H., Miller C. B., Carducci M., , Combined D NA, et al. Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. Cancer Res. 2006; 66(12)6361–6369
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G., Kantarjian H. M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108(10)3271–3279
   PubMed Web of Science ®Google Scholar
• Farag S. S., Archer K. J., Mrozek K., Ruppert A. S., Carroll A. J., Vardiman J. W., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108(1)63–73
   PubMed Web of Science ®Google Scholar
• Suvas S., Singh V., Sahdev S., et al. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J. Biol. Chem. 2002; 277: 7766–7775
   PubMed Web of Science ®Google Scholar
• Sariharan K., Anderson D., Leigh B., et al. Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma. Blood 2001; 98: 608a, (abstract 2549)
   Web of Science ®Google Scholar
• Czuczman M. S., Thall A., Witzig T. E., et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 2005; 23(19)4390–4398
   PubMed Web of Science ®Google Scholar
• Leonard J. P., Friedberg J. W., Younes A., et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology Advance Access published on April 29. 2007, doi:10.1093/annonc/mdm114
   Google Scholar
• Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362(9392)1255–1260
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 2005; 23(25)5960–5972
   PubMed Web of Science ®Google Scholar
• Wright J. R., Ung Y. C., Julian J. A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 2007; 25(9)1027–1032
   PubMed Web of Science ®Google Scholar
• Glaspy J., Smith R., Aapro M., et al. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy. Proceedings of the European Society of Haematology. 2007, abstract 0377
   Google Scholar
• Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta- analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006; 98(10)708–714
   PubMed Web of Science ®Google Scholar
• Bohlius J., Wilson J., Seidenfeld J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 2006; 3
   Google Scholar
• Wilson J., Yao G. L., Raftery J., et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 2007; 11(13)1–220
   PubMed Web of Science ®Google Scholar
• Elliott S., Busse L., Bass M. B., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107(5)1892–1895
   PubMed Web of Science ®Google Scholar
• Brown W. M., Maxwell P., Graham A. N., et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem. Cells 2007; 25(3)718–722
   PubMed Web of Science ®Google Scholar
• Osterborg A., Aapro M., Cornes P., Haselbeck A., Hayward C. R., Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007; 43(3)510–519
   PubMed Web of Science ®Google Scholar
• Jelkmann W., Laugsch M. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 2007; 25(12)1627–1628
   PubMed Web of Science ®Google Scholar
• Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., Garcia-Manero G., Wierda W., Pierce S., Shan J., Estey E. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome—predictive prognostic models for outcome. Cancer 2006; 106: 1090–1098
   PubMed Web of Science ®Google Scholar
• Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., Cauchie C., Peetermans M., Solbu G., Suciu S. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol. 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Tilly H., Castaigne S., Bordessoule D., Casassus P., Le Prise P., Tertian G., Desablens B., Henry-Amar M., Degos L. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol. 1990; 8: 272–279
   PubMed Web of Science ®Google Scholar
• Menzin J., Lang K., Earle C., Kerney D., Mallick R. The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly. Arch Intern Med 2002; 162: 1597–1603
   PubMed Web of Science ®Google Scholar
• Grimwade D., Walker H., Oliver F., Chatters S., Harrison G., Wheatley K., Burnett A., Goldstone A. The importance of diagnostic cytogenetics in older patients with AML: analysis of 922 patients entered into the MRC AML11 trial. Brit. J. Haematol. 1999; 105(1)67
   Google Scholar
• Farag S., Archer K., Mrózek K., Ruppert A., Carroll A., Vardiman A., Pettenati M., Baer M., Qumsiyeh M., Koduru P., Ning Y., Mayer R., Stone R., Larson R., Bloomfield C. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 63–73
   PubMed Web of Science ®Google Scholar
• Burnett A., Milligan D., Prentice A., Goldstone A., McMullin M., Hills R., Wheatley K. On behalf of the National Cancer Research Institute Haematological Oncology Study Group Adult Leukaemia Working Party. A comparison of low dose ara-C and hydroxyurea with or without all transretinoic acid in patients with acute myeloid leukaemia and high risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114–1124
   Google Scholar
• Lancet J., Gotlib J., Gojo I., Feldman E., Morris L., Thibault A., Liesveld J., Greer J., Dugan K., Raponi M., Wright J., Greenberg P., Karp J. Tipifarnib (ZARNESTRA?) in previously untreated poor-risk AML of the elderly: updated results of a multicenter phase 2 trial. Blood 2004; 104: 249a, (Abst 874)
   Web of Science ®Google Scholar
• Estey E., Garcia-Manero G., Giles F., Cortes J., O'Brien S., Kantarjian H. Clinical relevance of CRp in untreated AML [abst 541]. Blood 2005; 106: 161a
   Web of Science ®Google Scholar
• Berger M., Leopold L., Dowell J., Korth-Bradley J., Sherman M. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Inv. New Drugs 2002; 20: 395–406
   PubMed Web of Science ®Google Scholar
• Faderl S., Gandhi V., Keating M., Jeha S., Plunkett W., Kantarjian H. The role of clofarabine in hematologic and solid malignancies-Development of a next-generation nucleoside analog. Cancer 2005; 103: 1985–1995
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Gandhi V., Cortes J., Verstovsek S., Du M., Garcia-Manero G., Giles F., Faderl S., O'Brien S., Jeha S., Davis J., Shaked Z., Craig A., Keating M., Plunkett W., Freireich E. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 2379–2386
   PubMed Web of Science ®Google Scholar
• Faderl S., Verstovsek S., Cortes J., Ravandi F., Beran M., Garcia-Manero G., Ferrajoli A., Estrov Z., O'Brien S., Koller C., Giles F., Wierda W., Kwari M., Kantarjian H. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45–51
   PubMed Web of Science ®Google Scholar
• Burnett A., Russell N., Well J., Milligan D., Culligan D. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004; 104: 248a, (abst 869)
   Web of Science ®Google Scholar
• Burnett A., Baccarani M., Johnson P., Yin J., Russell N. Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy. J. Clin. Oncol. (Proceeding of ASCO) 2006; 24, (abst 6513)
   Google Scholar
• Kantarjian H., Issa J. P., Rosenfeld C. S., Bennett J. M., Albitar M., DiPersio J., Klimek V., Slack J., de Castro C., Ravandi F., Helmer R., Shen L., Nimer S. D., Leavitt R., Raza A., Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803
   PubMed Web of Science ®Google Scholar
• Lewis Silverman R., Erin P., Bercedis Demakos, Peterson L., Alice Kornblith B, Jimmie Holland C, Odchimar-Reissig Rosalie, Stone Richard M., Nelson Douglas, Powell Bayard L., DeCastro Carlos M., Ellerton John, Larson Richard A., Schiffer Charles A., Holland James F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440
   PubMed Web of Science ®Google Scholar
• Kaminskas Farrell E., Abraham A., Baird A. S., Hsieh L-S, Lee S-L, Leighton K., Patel H., Rahman A., Sridhara R., Wang Y.-C., Pazdur R. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 2005; 11: 3604–3608
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., Faderl S., Bueso-Ramos C., Ravandi F., Estrov Z., Ferrajoli A., Wierda W., Shan J., Davis J., Giles F., Saba H., Issa J. P. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
   PubMed Web of Science ®Google Scholar
• Kantarjian H., O'Brien S., Huang X., Garcia-Manero G., Giles F., Wierda W., Ferrajoli A., Ravandi F., Cortes J., Faderl S., Shan J., Davisson J., Bueso-Ramos C., Issa J. P. Survival advantage with decitabine versus intensive chemotherapy in patients with higher-risk myelodysplastic syndrome – comparison to historical experience. Cancer 2007; 109: 1133–37
   PubMed Web of Science ®Google Scholar
• Lubbert M., Buter B., Schmid M., Knipp S., Germing U., Dobbelstein C., Eimermacher H., Deschler B., Claus R., Schlenk R., Ganser A., Dohner H., Schmoor C., Henss H. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: first results of a multicenter phase II study. Blood 2005; 106: 527a, (abst 1852)
   Web of Science ®Google Scholar
• Silverman L., McKenzie D., Peterson B., Holland J., Backstrom J., Beach C., Larson R. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006; 24: 3895–3903
   PubMed Web of Science ®Google Scholar
• Giles F., O'Brien S., Rizzieri D., Karp J., Cooper M., Mufti G., Johnson B., Karsten V., Vey N. CLORETAZINE? (VNP40101M) is active in elderly untreated poor risk patient with acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS). Blood 2005; 106: 781a, (abst 2786)
   Web of Science ®Google Scholar
• Plunkett W., Garcia-Manero G., Faderl S., Cortes J., Boone P., Hilbe C., Green S., Chiao J. H., Kantarjian H. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes. JCO 2007; 25, abst 7063
   Google Scholar
• Roboz Gail. European Hematology Association, AmsterdamThe Netherlands June, 2006, (abst 978)
   Google Scholar
• Druker B. J., Guilhot F., O'Brien S G., et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate versus interferon alfa based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 2006; 108: 1835–1840
   PubMed Web of Science ®Google Scholar
• Corbin A. S., Rosee P. L., Stoffregen E. P., Druker B. J., Deininger M W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614
   PubMed Web of Science ®Google Scholar
• Donato N. J., Wu J. Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677
   PubMed Web of Science ®Google Scholar
• Shah N. P., Tran C., Lee F. Y., Chen P., Norris D., Sawyers C L. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• O'Hare T., Walters D., Stoffregen E., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500–4505
   PubMed Web of Science ®Google Scholar
• Talpaz M., Shah N. P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531–41
   PubMed Web of Science ®Google Scholar
• Hochhaus A., Kantarjian H., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309
   PubMed Web of Science ®Google Scholar
• Guilhot F., Apperley J., Kim D-W, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143–4150
   PubMed Web of Science ®Google Scholar
• Cortes J., Rousselot P., Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007; 109: 5143–5150
   PubMed Web of Science ®Google Scholar
• Shah N. P., Kim D. W., Kantarjian H. M., et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One –year results of CA 180034. J Clin Oncol 2007; 25, abstract 7004
   Google Scholar
• Pasquini R., Ottmann O. G., Goh Y. T., et al. Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph)+) ALL resistant or intolerant to imatinib: One year results of CA 180-035. J Clin Oncol 2007; 25, abstract 7025
   Google Scholar
• Atallah E. L., Kantarjian H., O'Brien S., et al. Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML). J Clin Oncol 2007; 25, abstract 7005
   Google Scholar
• Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542–51
   PubMed Web of Science ®Google Scholar
• Rosti G., Le Coutre P., Bhalla K., et al. A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol 2007; 25, abstract 7007
   Google Scholar
• Le Coutre P., Gatterman N., Hochhaus A., et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). J Clin Oncol 2007; 25, abstract 7006
   Google Scholar
• Larson R., Ottmann O., Kantarjian H., et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol 2007; 25, abstract 7040
   Google Scholar
• Mueller M. C., Branford S., Radich J., et al. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. J Clin Oncol 2007; 25, abstract 7024. J. Clin. Oncol., 2007, 25, abstract 7024
   Google Scholar
• Gambacorti-Passerini C., Blummedorf T., Kantarjian H., et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or AML who failed imatinib. J Clin Oncol 2007; 25, abstract 7006
   Google Scholar
• Craig A. R., Kantarjian H. M., Cortes J. E., et al. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (PH+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J. Clin. Oncol. 2007; 25, abstract 7046
   Google Scholar
• Cartron G., Watier H., Golay J., Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104(9)2635–42
   PubMed Web of Science ®Google Scholar
• Uppenkamp M., Engert A., Diehl V., et al. Monoclonal antibody therapy with campath-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann. Hematol. 2002; 81(1)26–32
   PubMed Web of Science ®Google Scholar
• Leonard J. P., Coleman M., Ketas J. C., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 2003; 21(16)3011–2
   PubMedGoogle Scholar
• Czuczman M. S., Thall A., Witzig T. E., et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 2005; 23(19)4390–8
   PubMed Web of Science ®Google Scholar
• deVos S., Dakil S., McLaughlin P., et al. Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study. Blood 2005; 106: 10a, (abstract 17)
   Web of Science ®Google Scholar
• Leonard J. P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23(22)5044–51
   PubMed Web of Science ®Google Scholar
• Leonard J. P., Friedberg J., Younes A., et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007, epub ahead of print
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Vose J., Pietronigro D, et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Proc ASCO 2007, Abstract 8066
   Google Scholar
• Raza A. F., Reeves J. E., Feldman E. J., et al. Long-term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without Del 5q cytogenetic abnormalities. Blood 2006; 108: 78a, (abstract 250)
   Web of Science ®Google Scholar
• List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 2006; 355: 1456–65
   PubMed Web of Science ®Google Scholar